Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

NCT04652882

Status	RECRUITING
Phase	Phase 3
Sponsor	Vanda Pharmaceuticals
Enrollment	70 participants

Key Eligibility Criteria

Inclusion (4)

- Ability and acceptance to provide written informed consent.
- A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD).
- Men or women between 18 - 75 years, inclusive.
- Body Mass Index (BMI) of e 18 and d 35 kg/m\^2.

Exclusion (5)

- Exacerbation of an existing psychiatric condition that requires change in treatment or intervention in the past 3 months.
- Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days.
- Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding.
- A positive test for substances of abuse.
- Current tobacco user.

Locations (17 total)

Vanda Investigational Site, Los Angeles, California, United States
Vanda Investigational Site, Redwood City, California, United States
Vanda Investigational Site, Aurora, Colorado, United States
... and 14 more locations